Letters to the Editor
Vol. 14 No. 2 (2020)
Antirheumatic in SARS-CoV-2: benefit or risk?
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 15 April 2020
Accepted: 28 April 2020
Accepted: 28 April 2020
2094
Views
629
Downloads
6
HTML
Authors
Not available
Downloads
Download data is not yet available.
Citations
How to Cite
Antirheumatic in SARS-CoV-2: benefit or risk?. (2020). Italian Journal of Medicine, 14(2), 114-115. https://doi.org/10.4081/itjm.2020.1290